Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

@inproceedings{Mesplde2012ViralFC,
  title={Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure},
  author={Thibault Mespl{\`e}de and Peter Kojo Quashie and Nathan Osman and Yingshan Han and Diane N. Singhroy and Yolanda S Lie and Christos J. Petropoulos and Wei Liang Huang and Mark A. Wainberg},
  booktitle={Retrovirology},
  year={2012}
}
BackgroundClinical studies have shown that integrase strand transfer inhibitors can be used to treat HIV-1 infection. Although the first-generation integrase inhibitors are susceptible to the emergence of resistance mutations that impair their efficacy in therapy, such resistance has not been identified to date in drug-naïve patients who have been treated with the second-generation inhibitor dolutegravir. During previous in vitro selection study, we identified a R263K mutation as the most… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 70 CITATIONS, ESTIMATED 58% COVERAGE

Resistance mutations ag ainst dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors

Maureen Oliveiraa, Thibault Mesplèdea, Peter K. Quashiea, Daniela Moı̈sia, Mark A. Wainberga
  • 2014
VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.

  • Antimicrobial agents and chemotherapy
  • 2013
VIEW 9 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.

  • Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  • 2016
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 12 Highly Influenced Citations

  • Averaged 7 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 35 REFERENCES

Resistance to HIV integrase inhibitors.

  • Current opinion in HIV and AIDS
  • 2012
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Dolutegravir for the treatment of HIV.

  • Expert opinion on investigational drugs
  • 2012
VIEW 3 EXCERPTS

Elvitegravir: a once-daily inhibitor of HIV-1 integrase.

  • Expert opinion on investigational drugs
  • 2012
VIEW 1 EXCERPT